Robertson Stephens Wealth Management LLC Acquires Shares of 2,800 Alnylam Pharmaceuticals, Inc. $ALNY

Robertson Stephens Wealth Management LLC acquired a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 2,800 shares of the biopharmaceutical company’s stock, valued at approximately $1,113,000.

A number of other hedge funds have also modified their holdings of the business. Mediolanum International Funds Ltd purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $11,389,000. Rakuten Investment Management Inc. purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $14,205,000. Generali Asset Management SPA SGR raised its position in Alnylam Pharmaceuticals by 6,368.0% in the 3rd quarter. Generali Asset Management SPA SGR now owns 3,234 shares of the biopharmaceutical company’s stock valued at $1,475,000 after purchasing an additional 3,184 shares during the last quarter. Cerity Partners LLC raised its position in Alnylam Pharmaceuticals by 171.2% in the 3rd quarter. Cerity Partners LLC now owns 27,429 shares of the biopharmaceutical company’s stock valued at $12,507,000 after purchasing an additional 17,316 shares during the last quarter. Finally, Campbell & CO Investment Adviser LLC purchased a new stake in Alnylam Pharmaceuticals in the 3rd quarter valued at $5,790,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Alnylam Pharmaceuticals

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Q1 beat driven by Amvuttra — Alnylam reported Q1 EPS of $1.99 and revenue of $1.17B, topping estimates; Amvuttra sales surged ~187% and helped drive 96% year?over?year revenue growth. Read More.
• Positive Sentiment: Brokerage support — Several brokerages continue to rate ALNY favorably (consensus around “moderate buy” and H.C. Wainwright remains a buy), which supports upside sentiment over the medium term. Read More.
• Neutral Sentiment: Mixed analyst target moves — Wells Fargo nudged its target slightly higher but kept an “equal weight” stance; RBC trimmed its target marginally but maintains an “outperform” view (still implying sizeable upside). These are tweaks rather than directional shifts. Read More. Read More.
• Neutral Sentiment: Investor materials and commentary available — Full earnings slide deck and call transcript were published (useful for modeling product-level trends and guidance; contributes to re?rating discussions). Read More.
• Negative Sentiment: Risks and product headwinds — The quarter showed declines in collaborator revenue and Onpattro sales that offset some gains; an outside review highlighted a new regulatory risk and warned the stock could carry a higher risk of significant losses, which likely pressured sentiment. Read More.

Insider Activity

In related news, EVP Pushkal Garg sold 2,242 shares of the company’s stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $695,199.36. Following the transaction, the executive vice president owned 24,848 shares of the company’s stock, valued at $7,704,867.84. This represents a 8.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Kevin Joseph Fitzgerald sold 2,041 shares of the company’s stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $331.96, for a total value of $677,530.36. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at $7,058,797.44. This represents a 8.76% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 38,656 shares of company stock valued at $12,370,696 over the last three months. 0.86% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several analysts recently commented on the stock. Bank of America reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. Chardan Capital reissued a “buy” rating and issued a $425.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, March 25th. Jefferies Financial Group restated a “hold” rating and set a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Royal Bank Of Canada cut their price target on Alnylam Pharmaceuticals from $450.00 to $445.00 and set an “outperform” rating for the company in a research note on Friday. Finally, Barclays began coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 28th. They set an “overweight” rating and a $527.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $471.96.

Alnylam Pharmaceuticals Price Performance

Alnylam Pharmaceuticals stock opened at $296.11 on Monday. Alnylam Pharmaceuticals, Inc. has a 12 month low of $245.96 and a 12 month high of $495.55. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.13 and a quick ratio of 3.06. The business has a 50 day simple moving average of $320.11 and a 200-day simple moving average of $376.18. The stock has a market capitalization of $39.51 billion, a PE ratio of 80.90 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.90 by $1.09. Alnylam Pharmaceuticals had a return on equity of 85.76% and a net margin of 11.72%.The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. During the same quarter in the prior year, the business earned ($0.44) earnings per share. The company’s quarterly revenue was up 96.4% compared to the same quarter last year. Equities analysts predict that Alnylam Pharmaceuticals, Inc. will post 6.78 earnings per share for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.